Rounder Inc., (Pink OTC Market: RNDR) medical division has acquired the
formulation rights for a heart healthy nutraceutical product. Roughly
one-third of adults use nutraceuticals and 15 million Americans use them
together with conventional medicines. A study from the Mayo clinic found
that 61% of those 18 years of age and older had used a nutraceutical
over the past year. With sales of nutraceutical products increasing 25%
per year in the United States, the US market for nutraceuticals is
expected to reach $891 million in consumer purchases by 2013. Our
capture of just a small percentage of market share in this rapidly
growing industry segment should result in substantial revenue for the
Marketing and manufacturing for the newly acquired product is expected
in the first quarter of 2013 following the completion of the branding
process. Distribution is then expected to begin before the end of March
2013. While the company negotiates the purchase of additionalproducts,
we are actively developing strategic partners with marketing firms that
have a proven record of success relating to the development of retail
accounts and product distributers within the nutraceuticals market.
Our first product to enter into our Medical Products division is
classified as an anti-inflammatory, as the product assists in reducing
body inflammation. Chronic inflammation can have serious effects on the
human body. Science has made links between chronic inflammation and
various degenerative diseases including cancer, heart disease, diabetes,
Alzheimer's and many others. When inflammation occurs, chemicals such as
inflammatory cytokines are released into the blood or tissues.
Inflammatory cytokines are destructive to our normal cells.
As mentioned the company is actively seeking additional nutraceutical
products to build a dynamic product line. The products we seek will
assist in reducing coronary artery blockage, reduce all types of body
fat and lipid compounds, and generally increase the health of the human
In other events, the company has received approval from FINRA for our
name change, "Fortitude Group Inc." We still await our new trading
symbol. The company remains confident that our discussions involving the
acquisition of a medical device company will conclude successfully, and
we will provide further updates as they become relevant.
Safe Harbor This press release contains forward-looking statements. Such
forward-looking statements are subject to a number of risks, assumptions
and uncertainties that could cause the Company's actual results to
differ materially from those projected in such statements.
Forward-looking statements speak only as of the date made and are not
guarantees of future performance. We undertake no obligation to publicly
revise any forward-looking statements.
[ Back To NFVZone's Homepage ]